Compare Gigacloud Technology Inc (GCT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Organon & Co. Common Stock — how do they compare? Gigacloud Technology Inc trades at $56.9 (market cap $2.06B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 20 Days and Organon & Co. Common Stock for 0 Days on average.
| GCT | OGN | |
|---|---|---|
Market Cap | $2.06B | $3.61B |
Volume | 820,423 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $57.75 | $13.81 |
52-Week Low | $25.46 | $5.70 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $2.19B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.03, down 1.23% with a bullish technical outlook from moving averages but bearish oscillators. The company shows strong fundamentals with consistent earnings beats, 10.65% net margin, and 32.34% ROE. Revenue grew to $1.29B in 2025 with positive cash flow of $120.10M. Recent news highlights institutional interest and European expansion driving growth.
The stock presents value with a 13.75 P/E ratio but faces technical overbought signals and insider selling. Analyst consensus is bullish with $32.50 price target, though current price exceeds this. Key risks include market volatility and execution challenges in international expansion.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
